Bicycle Therapeutics (BCYC) Financials

Bicycle Therapeutics (NASDAQ: BCYC) remains well-funded, but its financial statements continue to show a development-stage biotechnology company with substantial operating losses and cash burn. In the second quarter of 2026, revenue declined to $629,000 from $887,000 in the first quarter and $2.9 million in the comparable quarter of 2025. The unusually high $47.955 million of revenue in the fourth quarter of 2025 appears inconsistent with the company’s recent quarterly run rate and may have reflected milestone or collaboration revenue.

• Cash reserves remain substantial. BCYC reported $510.1 million in cash and equivalents at June 30, 2026. Although this was down from $559.5 million at the end of the first quarter and $721.5 million at June 30, 2025, it provides meaningful funding flexibility.
• Quarterly cash burn improved sequentially. Net cash used in operating activities fell to $49.6 million in Q2 2026 from $65.9 million in Q1. Net cash declined by $50.0 million during the quarter, compared with a $68.6 million decrease in Q1.
• Operating expenses declined from the prior quarter. Research and development expense fell to $41.2 million from $48.9 million in Q1, while selling, general and administrative expense declined to $14.0 million from $17.5 million. Total operating expenses decreased 16.7% sequentially to $55.2 million.
• Interest income is helping offset operating losses. Interest and investment income contributed $4.4 million in Q2 2026, reducing the company’s pre-tax loss. BCYC also reported only $44,000 of interest expense, indicating limited debt-related pressure.
• The balance sheet has relatively low leverage. Total liabilities were $96.3 million compared with $510.3 million of equity and $510.1 million of cash. Debt repayments were only $51,000 during Q2, and the company does not appear dependent on debt financing to fund current operations.
• Liquidity appears sufficient for the near term, but runway estimates are sensitive to clinical spending. Using Q2’s approximately $50 million operating cash burn as a simple guide, the reported cash balance represents roughly 10 quarters of funding. Actual runway could change materially as clinical programs advance, expenses fluctuate or additional partnership payments are received.
• Deferred revenue remains a meaningful balance-sheet item. Current and noncurrent deferred revenue totaled approximately $40.0 million at June 30, 2026. This may represent future obligations to provide services or perform under collaboration agreements rather than immediately available revenue.
• BCYC remains deeply unprofitable. The company reported a Q2 net loss of $50.3 million, or $0.72 per diluted share. Losses have persisted throughout the supplied periods, with quarterly net losses generally ranging from approximately $20 million to $79 million.
• Revenue is small and volatile relative to spending. Q2 revenue of $629,000 covered only about 1% of quarterly operating expenses. Revenue has generally remained in the low-single-digit millions, apart from the $48.0 million reported in Q4 2025, leaving the business reliant on cash reserves, financing and potential collaboration milestones.
• Cash and shareholders’ equity have trended lower since 2024. Cash fell from $961.4 million in Q2 2024 to $510.1 million in Q2 2026, while total equity declined from $668.9 million in Q2 2025 to $510.3 million in Q2 2026. Weighted average basic shares also rose from 52.0 million in Q2 2024 to 69.8 million in Q2 2026, indicating meaningful dilution over the period.

Overall, BCYC’s financial position is supported by a sizable cash balance, minimal debt and some recent reduction in operating expenses. However, the company has not demonstrated a path to self-sustaining operations: revenue remains unpredictable, losses remain large and cash has declined steadily as research and development programs consume capital. Investors should focus on clinical progress, partnership or milestone revenue and whether quarterly cash burn continues to moderate.